Introduction. Mutations in circulating nucleic acids are biomarkers for the early detection and management of hepatocellular carcinoma (HCC). While circulating tumor DNA (ctDNA) and microRNA have been
Circulating tumor DNA (ctDNA) is a promising biomarker for accurate monitoring and less invasive assessment of tumor burden and treatment response. Here, targeted next-generation sequencing (NGS) with
Additional file 2: Table S1. C sites prone to incomplete conversion in EM-seq. Table S2. Quality control metrics for Targeted EM-seq using HCC cell line input from 5 to 20 ng. Table S3. Quality contro
Liquid biopsy, the analysis of body fluids, represents a promising approach for disease diagnosis and prognosis with minimal intervention. Sequencing cell-free RNA derived from liquid biopsies has bee
